New stroke treatment injection

You're referring to the recent breakthrough in stroke treatment!

In October 2022, the FDA approved a new treatment for acute ischemic stroke, which is a type of stroke caused by a blockage in the blood vessels supplying the brain. The treatment is called Lasojo (tenecteplase) and it's an injection that can be administered within 4.5 hours of the onset of symptoms.

Here's how it works:

1. The injection is given directly into the affected blood vessel through a catheter.
2. Tenecteplase is a clot-busting medication that dissolves the blood clot causing the blockage.
3. This helps restore blood flow to the brain, reducing the risk of long-term damage or death.

The benefits of this new treatment are significant:

1. Faster treatment: With Lasojo, patients can receive treatment within 4.5 hours of symptoms, which is faster than the previous 6-hour window.
2. Improved outcomes: Studies have shown that patients who receive Lasojo within the 4.5-hour window have better outcomes, including reduced risk of death, disability, and long-term damage.
3. Increased access: This treatment is available in hospitals and emergency centers, making it more accessible to patients who need it.

It's worth noting that Lasojo is not a replacement for established stroke treatments, such as tPA (tissue plasminogen activator), which has been used for decades. However, Lasojo offers an additional option for patients who may not be eligible for tPA or who require a more targeted treatment.

Overall, the approval of Lasojo is a significant breakthrough in stroke treatment, offering new hope for patients and their families affected by this devastating condition.